Advances in the Treatment of Non-Melanoma Skin Cancers: The Role of Immune Checkpoint Inhibitors

This activity was originally presented at the 2022 ASHP Midyear Clinical Meeting & Exposition.

Program Description

Systemic therapies for patients with advanced, unresectable, or metastatic basal cell carcinoma and cutaneous squamous cell carcinoma have only recently been incorporated in therapeutic plans. The use of immune checkpoint inhibitors (ICIs) offers patients with non-melanoma skin cancers improved outcomes, but treatment-related adverse effects are frequent and can lead to therapy discontinuation. Safety and efficacy for recently approved and emerging ICIs and combination regimens for patients with basal cell and squamous cell skin cancers will be reviewed. In addition to emerging treatments, oncology pharmacists must be familiar with the frequency of immune-related adverse events associated with ICI therapy and appropriate management strategies that balance improving patient outcomes while minimizing therapy interruption. This activity will feature discussion of patient cases with opportunities for participants to gain experience with treatment selection based on disease- and patient-specific factors.
Target audience: Health-system pharmacists, Oncology Pharmacists

Type of activity: Application
Release date: December 22, 2022
Expiration date: December 22, 2023

Time to complete activity: 1.5 hours
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Identify behavioral and therapeutic strategies for the prevention of non-melanoma skin cancers
• Customize treatment selection for patients with advanced or metastatic cutaneous squamous cell carcinoma or basal cell carcinoma based on clinical data, guideline recommendations, and patient-specific factors
• Employ strategies to mitigate cutaneous immune-related adverse events associated with immune checkpoint inhibitor therapy

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-22-620-H01-P. The activity is available for CE credit through December 22, 2023.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Jessica Michaud Davis, PharmD, BCOP, CPP, has the following financial relationships with commercial interests to disclose:

• Consultant: Exelixis, Inc. (advisory board), Sanofi/Regeneron (advisory board); Speaker’s Bureau: Exelixis, Inc.

Medical Reviewer Morgan Gwynn, PharmD, BCOP, CPP, has the following relevant financial relationship with a commercial interest to disclose:

• Consultant: Replimune Group, Inc.

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Heather Armbruster, PharmD, BCOP

Theresa Brown, PharmD, BCOP, CPP

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Amy H. Seung, PharmD, BCOP, FHOPA, CHCP; Abigail Dill; Susan Pordon; Brianna Winters; and Chloe Taccetta.

An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms